There are multiple testing modalities.
We have examined them decades ago.
Various other markers have been proposed.
Ase the UK has just announced:
The UK National Screening Committee (UK NSC) has
recommended that all UK nations implement targeted prostate cancer screening
for men aged 45 to 61 who have both a BRCA2 gene change that increases cancer
risk and a family history of breast, ovarian, pancreatic or prostate cancer. As part of this approach, eligible men would
be offered a prostate specific antigen (PSA) test every two years. This final recommendation modifies a draft
recommendation the UK NSC made in November 2025, which also included men with
BRCA1 gene changes. Since then, the committee has been consulting with
organisations, experts and the public, and considering the latest evidence on
the risks and benefits of screening these groups, among others. “Today’s announcement will be disappointing
for many people, but the PSA test currently used to help detect prostate cancer
isn’t effective enough to support wider screening, as shown in multiple
large-scale trials,” explains Dr Ian Walker, Cancer Research UK’s Executive
Director of Policy. “Screening should only be introduced when the benefits
outweigh the harms, including unnecessary and invasive overtreatment, and right
now, the evidence is only strong enough to screen men aged 45 to 61 with BRCA2
gene changes and a relevant family history.”
We now urge governments across the UK to accept the UK NSC’s
recommendation and begin to implement targeted screening. At the same time, they should continue to
invest in research that brings us closer to effective screening for more men.
We also aim to be part of that work. Over the past three years, Cancer Research
UK has invested £28m to find new and better ways to prevent, detect and treat
cancer, and we will continue to help more men affected by prostate cancer live
longer, better lives.
MedCityNews notes:
On Wednesday, 60 organizations representing providers and
patients with cancer submitted a letter to Robert F. Kennedy Jr., secretary of
Health and Human Services, urging him to protect the U.S. Preventive Services
Task Force (USPSTF). USPSTF is an
independent panel of experts in disease prevention. It provides recommendations
for clinical preventive services like screenings, counseling services and
medications. However, the task force
hasn’t convened in over a year. And last week, Kennedy fired the vice chairs of
USPSTF: John Wong, a professor of medicine at Tufts University, and Esa Davis,
professor of medicine at the University of Maryland.
Ironically the USPSTF had taken a stand comparable to the
UK, Namely, limit PSA testing. Just to put things in perspective, PSA and %Free
tests cost about $50. Here in the US one can get them at Quest and other Labs
without a doctors order. If one were to be tested ever six months, and the
results examined over time, then any significant change would present as a
warning.
We have shown decades ago that PSA was useful, but only if
examined in an ongoing temporal mode. Most physicians do not do this, they just
look at the most recent. Thus is one’s PSA goes from 1.2 to 2.8 in six months,
I would recommend another three months later and then a biopsy.
Your survival is in your hands. Is it worth $100 a year? I
would think so.